Skip to main content

Table 4 Pre- and post-booster immune response to pneumococcal polysaccharides (ATP persistence and booster ATP immunogenicity cohorts)

From: A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia

 

ClinCom group

ComCom group

 

Pre-booster dose

Post-booster dose

Pre-booster dose

Post-booster dose

 

N

% ≥0.2 μg/mL

GMC

N

% ≥0.2 μg/mL

GMC

N

% ≥0.2 μg/mL

GMC

N

% ≥0.2 μg/mL

GMC

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

Vaccine serotypes

Serotype 1

111

85.6

0.48

107

100

7.14

112

75.0

0.35

111

100

6.29

(77.6 – 91.5)

(0.40 – 0.57)

 

(96.6 – 100)

(6.12 – 8.32)

 

(65.9 – 82.7)

(0.30 – 0.41)

 

(96.7 – 100)

(5.38 – 7.35)

Serotype 4

107

86.9

0.56

106

100

7.53

106

82.1

0.48

109

100

7.43

(79.0 – 92.7)

(0.48 – 0.67)

 

(96.6 – 100)

(6.44 – 8.80)

 

(73.4 – 88.8)

(0.40 – 0.58)

 

(96.7 – 100)

(6.33 – 8.71)

Serotype 5

103

92.2

0.76

106

100

7.91

103

91.3

0.54

108

100

7.16

(85.3 – 96.6)

(0.65 – 0.89)

 

(96.6 – 100)

(6.91 – 9.06)

 

(84.1 – 95.9)

(0.47 – 0.63)

 

(96.6 – 100)

(6.25 – 8.20)

Serotype 6B

103

71.8

0.34

106

100

3.30

102

60.8

0.32

109

98.2

3.12

(62.1 – 80.3)

(0.29 – 0.40)

 

(96.6 – 100)

(2.85 – 3.81)

 

(50.6 – 70.3)

(0.25 – 0.41)

 

(93.5 – 99.8)

(2.59 – 3.76)

Serotype 7F

104

95.2

0.88

106

100

9.02

105

96.2

0.91

109

100

9.25

(89.1 – 98.4)

(0.75 – 1.03)

 

(96.6 – 100)

(7.77 – 10.47)

 

(90.5 – 99.0)

(0.78 – 1.07)

 

(96.7 – 100)

(8.04 – 10.64)

Serotype 9V

105

98.1

0.90

107

100

9.36

102

94.1

0.73

109

100

10.42

(93.3 – 99.8)

(0.77 – 1.06)

 

(96.6 – 100)

(8.15 – 10.75)

 

(87.6 – 97.8)

(0.62 – 0.85)

 

(96.7 – 100)

(8.94 – 12.14)

Serotype 14

105

93.3

1.06

106

100

13.03

100

93.0

0.91

106

100

13.28

(86.7 – 97.3)

(0.86 – 1.31)

 

(96.6 – 100)

(10.95 – 15.50)

 

(86.1 – 97.1)

(0.75 – 1.11)

 

(96.6 – 100)

(11.06 – 15.95)

Serotype 18C

109

92.7

0.83

106

100

19.80

108

92.6

0.78

108

100

24.19

(86.0 – 96.8)

(0.69 – 1.01)

 

(96.6 – 100)

(17.02 – 23.03)

 

(85.9 – 96.7)

(0.65 – 0.93)

 

(96.6 – 100)

(20.66 – 28.33)

Serotype 19F

103

98.1

1.10

106

100

19.68

103

99.0

0.96

108

100

20.55

(93.2 – 99.8)

(0.87 – 1.40)

 

(96.6 – 100)

(17.22 – 22.51)

 

(94.7 – 100)

(0.82 – 1.13)

 

(96.6 – 100)

(17.62 – 23.98)

Serotype 23F

108

83.3

0.66

107

99.1

7.19

106

79.2

0.47

109

100

6.83

(74.9 – 89.8)

(0.51 – 0.84)

 

(94.9 – 100)

(5.94 – 8.71)

 

(70.3 – 86.5)

(0.38 – 0.58)

 

(96.7 – 100)

(5.77 – 8.07)

Cross-reactive serotypes

Serotype 6A

109

53.2

0.23

106

99.1

2.13

111

45.0

0.21

108

97.2

1.99

(43.4 – 62.8)

(0.18 – 0.28)

 

(94.9 – 100)

(1.70 – 2.66)

 

(35.6 – 54.8)

(0.16 – 0.26)

 

(92.1 – 99.4)

(1.60 – 2.49)

Serotype 19A

112

49.1

0.18

106

93.4

2.13

109

46.8

0.19

109

96.3

2.96

(39.5 – 58.7)

(0.14 – 0.22)

 

(86.9 – 97.3)

(1.65 – 2.76)

 

(37.2 – 56.6)

(0.15 – 0.24)

 

(90.9 – 99.0)

(2.26 – 3.87)

  1. ClinCom = group of toddlers from Singapore primed with the Phase III Clinical lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase.
  2. ComCom = group of toddlers from Singapore primed with the Commercial lot of PHiD-CV who received the Commercial lot of PHiD-CV in the booster vaccination phase.
  3. N = number of participants with available results.
  4. 95% CI = 95% confidence interval.
  5. % = percentage of infants with antibody concentrations above the specified cut-off.
  6. GMC = geometric mean concentration.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us